nodes	percent_of_prediction	percent_of_DWPC	metapath
Pramipexole—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000162	0.000235	CcSEcCtD
Pramipexole—Sweating—Epirubicin—pancreatic cancer	0.000161	0.000234	CcSEcCtD
Pramipexole—Pollakiuria—Doxorubicin—pancreatic cancer	0.000161	0.000234	CcSEcCtD
Pramipexole—Asthenia—Gemcitabine—pancreatic cancer	0.00016	0.000233	CcSEcCtD
Pramipexole—Haematuria—Epirubicin—pancreatic cancer	0.00016	0.000233	CcSEcCtD
Pramipexole—Confusional state—Docetaxel—pancreatic cancer	0.00016	0.000233	CcSEcCtD
Pramipexole—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000159	0.000231	CcSEcCtD
Pramipexole—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000159	0.000231	CcSEcCtD
Pramipexole—Oedema—Docetaxel—pancreatic cancer	0.000159	0.000231	CcSEcCtD
Pramipexole—Weight increased—Doxorubicin—pancreatic cancer	0.000158	0.00023	CcSEcCtD
Pramipexole—Epistaxis—Epirubicin—pancreatic cancer	0.000158	0.00023	CcSEcCtD
Pramipexole—Pruritus—Gemcitabine—pancreatic cancer	0.000158	0.00023	CcSEcCtD
Pramipexole—Infection—Docetaxel—pancreatic cancer	0.000157	0.000229	CcSEcCtD
Pramipexole—Weight decreased—Doxorubicin—pancreatic cancer	0.000157	0.000229	CcSEcCtD
Pramipexole—Sinusitis—Epirubicin—pancreatic cancer	0.000157	0.000229	CcSEcCtD
Pramipexole—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000157	0.000228	CcSEcCtD
Pramipexole—Diarrhoea—Irinotecan—pancreatic cancer	0.000157	0.000228	CcSEcCtD
Pramipexole—Pneumonia—Doxorubicin—pancreatic cancer	0.000156	0.000227	CcSEcCtD
Pramipexole—Shock—Docetaxel—pancreatic cancer	0.000156	0.000227	CcSEcCtD
Pramipexole—Nervous system disorder—Docetaxel—pancreatic cancer	0.000155	0.000226	CcSEcCtD
Pramipexole—Pruritus—Fluorouracil—pancreatic cancer	0.000155	0.000226	CcSEcCtD
Pramipexole—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000155	0.000226	CcSEcCtD
Pramipexole—Infestation—Doxorubicin—pancreatic cancer	0.000155	0.000226	CcSEcCtD
Pramipexole—Infestation NOS—Doxorubicin—pancreatic cancer	0.000155	0.000226	CcSEcCtD
Pramipexole—Drowsiness—Doxorubicin—pancreatic cancer	0.000155	0.000226	CcSEcCtD
Pramipexole—Tachycardia—Docetaxel—pancreatic cancer	0.000155	0.000225	CcSEcCtD
Pramipexole—Skin disorder—Docetaxel—pancreatic cancer	0.000154	0.000224	CcSEcCtD
Pramipexole—Bradycardia—Epirubicin—pancreatic cancer	0.000153	0.000223	CcSEcCtD
Pramipexole—Diarrhoea—Gemcitabine—pancreatic cancer	0.000153	0.000222	CcSEcCtD
Pramipexole—Renal failure—Doxorubicin—pancreatic cancer	0.000152	0.000222	CcSEcCtD
Pramipexole—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.000152	0.000221	CcSEcCtD
Pramipexole—Dizziness—Irinotecan—pancreatic cancer	0.000152	0.000221	CcSEcCtD
Pramipexole—Anorexia—Docetaxel—pancreatic cancer	0.000151	0.00022	CcSEcCtD
Pramipexole—Rhinitis—Epirubicin—pancreatic cancer	0.000151	0.00022	CcSEcCtD
Pramipexole—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000151	0.000219	CcSEcCtD
Pramipexole—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000151	0.000219	CcSEcCtD
Pramipexole—Diarrhoea—Fluorouracil—pancreatic cancer	0.00015	0.000219	CcSEcCtD
Pramipexole—Hypoaesthesia—Epirubicin—pancreatic cancer	0.00015	0.000218	CcSEcCtD
Pramipexole—Pharyngitis—Epirubicin—pancreatic cancer	0.000149	0.000217	CcSEcCtD
Pramipexole—Sweating—Doxorubicin—pancreatic cancer	0.000149	0.000216	CcSEcCtD
Pramipexole—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000149	0.000216	CcSEcCtD
Pramipexole—Oedema peripheral—Epirubicin—pancreatic cancer	0.000148	0.000216	CcSEcCtD
Pramipexole—Hypotension—Docetaxel—pancreatic cancer	0.000148	0.000216	CcSEcCtD
Pramipexole—Haematuria—Doxorubicin—pancreatic cancer	0.000148	0.000215	CcSEcCtD
Pramipexole—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000148	0.000215	CcSEcCtD
Pramipexole—Urethral disorder—Epirubicin—pancreatic cancer	0.000148	0.000215	CcSEcCtD
Pramipexole—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000147	0.000214	CcSEcCtD
Pramipexole—Epistaxis—Doxorubicin—pancreatic cancer	0.000146	0.000213	CcSEcCtD
Pramipexole—Vomiting—Irinotecan—pancreatic cancer	0.000146	0.000212	CcSEcCtD
Pramipexole—Sinusitis—Doxorubicin—pancreatic cancer	0.000146	0.000212	CcSEcCtD
Pramipexole—Dizziness—Fluorouracil—pancreatic cancer	0.000145	0.000211	CcSEcCtD
Pramipexole—Visual impairment—Epirubicin—pancreatic cancer	0.000145	0.000211	CcSEcCtD
Pramipexole—Rash—Irinotecan—pancreatic cancer	0.000145	0.00021	CcSEcCtD
Pramipexole—Dermatitis—Irinotecan—pancreatic cancer	0.000144	0.00021	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000144	0.00021	CcSEcCtD
Pramipexole—Headache—Irinotecan—pancreatic cancer	0.000144	0.000209	CcSEcCtD
Pramipexole—Insomnia—Docetaxel—pancreatic cancer	0.000143	0.000209	CcSEcCtD
Pramipexole—Paraesthesia—Docetaxel—pancreatic cancer	0.000142	0.000207	CcSEcCtD
Pramipexole—Vomiting—Gemcitabine—pancreatic cancer	0.000142	0.000207	CcSEcCtD
Pramipexole—Bradycardia—Doxorubicin—pancreatic cancer	0.000142	0.000206	CcSEcCtD
Pramipexole—Dyspnoea—Docetaxel—pancreatic cancer	0.000141	0.000206	CcSEcCtD
Pramipexole—Somnolence—Docetaxel—pancreatic cancer	0.000141	0.000205	CcSEcCtD
Pramipexole—Rash—Gemcitabine—pancreatic cancer	0.000141	0.000205	CcSEcCtD
Pramipexole—Dermatitis—Gemcitabine—pancreatic cancer	0.000141	0.000205	CcSEcCtD
Pramipexole—Eye disorder—Epirubicin—pancreatic cancer	0.000141	0.000205	CcSEcCtD
Pramipexole—Tinnitus—Epirubicin—pancreatic cancer	0.00014	0.000204	CcSEcCtD
Pramipexole—Headache—Gemcitabine—pancreatic cancer	0.00014	0.000204	CcSEcCtD
Pramipexole—Cardiac disorder—Epirubicin—pancreatic cancer	0.00014	0.000203	CcSEcCtD
Pramipexole—Flushing—Epirubicin—pancreatic cancer	0.00014	0.000203	CcSEcCtD
Pramipexole—Vomiting—Fluorouracil—pancreatic cancer	0.00014	0.000203	CcSEcCtD
Pramipexole—Rhinitis—Doxorubicin—pancreatic cancer	0.00014	0.000203	CcSEcCtD
Pramipexole—Dyspepsia—Docetaxel—pancreatic cancer	0.00014	0.000203	CcSEcCtD
Pramipexole—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000139	0.000202	CcSEcCtD
Pramipexole—Rash—Fluorouracil—pancreatic cancer	0.000138	0.000202	CcSEcCtD
Pramipexole—Dermatitis—Fluorouracil—pancreatic cancer	0.000138	0.000201	CcSEcCtD
Pramipexole—Pharyngitis—Doxorubicin—pancreatic cancer	0.000138	0.000201	CcSEcCtD
Pramipexole—Decreased appetite—Docetaxel—pancreatic cancer	0.000138	0.000201	CcSEcCtD
Pramipexole—Headache—Fluorouracil—pancreatic cancer	0.000138	0.0002	CcSEcCtD
Pramipexole—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000138	0.0002	CcSEcCtD
Pramipexole—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000137	0.0002	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000137	0.000199	CcSEcCtD
Pramipexole—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000137	0.000199	CcSEcCtD
Pramipexole—Fatigue—Docetaxel—pancreatic cancer	0.000137	0.000199	CcSEcCtD
Pramipexole—Angiopathy—Epirubicin—pancreatic cancer	0.000137	0.000199	CcSEcCtD
Pramipexole—Urethral disorder—Doxorubicin—pancreatic cancer	0.000136	0.000199	CcSEcCtD
Pramipexole—Nausea—Irinotecan—pancreatic cancer	0.000136	0.000198	CcSEcCtD
Pramipexole—Immune system disorder—Epirubicin—pancreatic cancer	0.000136	0.000198	CcSEcCtD
Pramipexole—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000136	0.000197	CcSEcCtD
Pramipexole—Pain—Docetaxel—pancreatic cancer	0.000136	0.000197	CcSEcCtD
Pramipexole—Constipation—Docetaxel—pancreatic cancer	0.000136	0.000197	CcSEcCtD
Pramipexole—Chills—Epirubicin—pancreatic cancer	0.000135	0.000197	CcSEcCtD
Pramipexole—Visual impairment—Doxorubicin—pancreatic cancer	0.000134	0.000195	CcSEcCtD
Pramipexole—Alopecia—Epirubicin—pancreatic cancer	0.000133	0.000194	CcSEcCtD
Pramipexole—Nausea—Gemcitabine—pancreatic cancer	0.000133	0.000193	CcSEcCtD
Pramipexole—Mental disorder—Epirubicin—pancreatic cancer	0.000132	0.000192	CcSEcCtD
Pramipexole—Erythema—Epirubicin—pancreatic cancer	0.000131	0.000191	CcSEcCtD
Pramipexole—Malnutrition—Epirubicin—pancreatic cancer	0.000131	0.000191	CcSEcCtD
Pramipexole—Feeling abnormal—Docetaxel—pancreatic cancer	0.000131	0.00019	CcSEcCtD
Pramipexole—Nausea—Fluorouracil—pancreatic cancer	0.00013	0.00019	CcSEcCtD
Pramipexole—Eye disorder—Doxorubicin—pancreatic cancer	0.00013	0.000189	CcSEcCtD
Pramipexole—Tinnitus—Doxorubicin—pancreatic cancer	0.00013	0.000189	CcSEcCtD
Pramipexole—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.00013	0.000189	CcSEcCtD
Pramipexole—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000129	0.000188	CcSEcCtD
Pramipexole—Flushing—Doxorubicin—pancreatic cancer	0.000129	0.000188	CcSEcCtD
Pramipexole—Flatulence—Epirubicin—pancreatic cancer	0.000129	0.000188	CcSEcCtD
Pramipexole—Tension—Epirubicin—pancreatic cancer	0.000129	0.000187	CcSEcCtD
Pramipexole—Dysgeusia—Epirubicin—pancreatic cancer	0.000128	0.000187	CcSEcCtD
Pramipexole—Nervousness—Epirubicin—pancreatic cancer	0.000127	0.000185	CcSEcCtD
Pramipexole—Back pain—Epirubicin—pancreatic cancer	0.000127	0.000184	CcSEcCtD
Pramipexole—Angiopathy—Doxorubicin—pancreatic cancer	0.000126	0.000184	CcSEcCtD
Pramipexole—Muscle spasms—Epirubicin—pancreatic cancer	0.000126	0.000183	CcSEcCtD
Pramipexole—Immune system disorder—Doxorubicin—pancreatic cancer	0.000126	0.000183	CcSEcCtD
Pramipexole—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000125	0.000183	CcSEcCtD
Pramipexole—Abdominal pain—Docetaxel—pancreatic cancer	0.000125	0.000182	CcSEcCtD
Pramipexole—Body temperature increased—Docetaxel—pancreatic cancer	0.000125	0.000182	CcSEcCtD
Pramipexole—Chills—Doxorubicin—pancreatic cancer	0.000125	0.000182	CcSEcCtD
Pramipexole—Vision blurred—Epirubicin—pancreatic cancer	0.000123	0.00018	CcSEcCtD
Pramipexole—Alopecia—Doxorubicin—pancreatic cancer	0.000123	0.000179	CcSEcCtD
Pramipexole—Mental disorder—Doxorubicin—pancreatic cancer	0.000122	0.000178	CcSEcCtD
Pramipexole—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000122	0.000177	CcSEcCtD
Pramipexole—Erythema—Doxorubicin—pancreatic cancer	0.000121	0.000176	CcSEcCtD
Pramipexole—Malnutrition—Doxorubicin—pancreatic cancer	0.000121	0.000176	CcSEcCtD
Pramipexole—Anaemia—Epirubicin—pancreatic cancer	0.000121	0.000176	CcSEcCtD
Pramipexole—Agitation—Epirubicin—pancreatic cancer	0.00012	0.000175	CcSEcCtD
Pramipexole—Flatulence—Doxorubicin—pancreatic cancer	0.000119	0.000174	CcSEcCtD
Pramipexole—Tension—Doxorubicin—pancreatic cancer	0.000119	0.000173	CcSEcCtD
Pramipexole—Dysgeusia—Doxorubicin—pancreatic cancer	0.000119	0.000173	CcSEcCtD
Pramipexole—Malaise—Epirubicin—pancreatic cancer	0.000118	0.000172	CcSEcCtD
Pramipexole—Nervousness—Doxorubicin—pancreatic cancer	0.000118	0.000171	CcSEcCtD
Pramipexole—Vertigo—Epirubicin—pancreatic cancer	0.000118	0.000171	CcSEcCtD
Pramipexole—Syncope—Epirubicin—pancreatic cancer	0.000117	0.000171	CcSEcCtD
Pramipexole—Leukopenia—Epirubicin—pancreatic cancer	0.000117	0.000171	CcSEcCtD
Pramipexole—Back pain—Doxorubicin—pancreatic cancer	0.000117	0.000171	CcSEcCtD
Pramipexole—Hypersensitivity—Docetaxel—pancreatic cancer	0.000117	0.00017	CcSEcCtD
Pramipexole—Muscle spasms—Doxorubicin—pancreatic cancer	0.000117	0.00017	CcSEcCtD
Pramipexole—Palpitations—Epirubicin—pancreatic cancer	0.000116	0.000169	CcSEcCtD
Pramipexole—Loss of consciousness—Epirubicin—pancreatic cancer	0.000115	0.000168	CcSEcCtD
Pramipexole—Cough—Epirubicin—pancreatic cancer	0.000114	0.000166	CcSEcCtD
Pramipexole—Vision blurred—Doxorubicin—pancreatic cancer	0.000114	0.000166	CcSEcCtD
Pramipexole—Asthenia—Docetaxel—pancreatic cancer	0.000114	0.000166	CcSEcCtD
Pramipexole—Convulsion—Epirubicin—pancreatic cancer	0.000114	0.000165	CcSEcCtD
Pramipexole—Hypertension—Epirubicin—pancreatic cancer	0.000113	0.000165	CcSEcCtD
Pramipexole—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000112	0.000164	CcSEcCtD
Pramipexole—Pruritus—Docetaxel—pancreatic cancer	0.000112	0.000163	CcSEcCtD
Pramipexole—Anaemia—Doxorubicin—pancreatic cancer	0.000112	0.000163	CcSEcCtD
Pramipexole—Arthralgia—Epirubicin—pancreatic cancer	0.000112	0.000162	CcSEcCtD
Pramipexole—Chest pain—Epirubicin—pancreatic cancer	0.000112	0.000162	CcSEcCtD
Pramipexole—Myalgia—Epirubicin—pancreatic cancer	0.000112	0.000162	CcSEcCtD
Pramipexole—Agitation—Doxorubicin—pancreatic cancer	0.000111	0.000162	CcSEcCtD
Pramipexole—Anxiety—Epirubicin—pancreatic cancer	0.000111	0.000162	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000111	0.000161	CcSEcCtD
Pramipexole—Discomfort—Epirubicin—pancreatic cancer	0.00011	0.00016	CcSEcCtD
Pramipexole—Malaise—Doxorubicin—pancreatic cancer	0.000109	0.000159	CcSEcCtD
Pramipexole—Dry mouth—Epirubicin—pancreatic cancer	0.000109	0.000159	CcSEcCtD
Pramipexole—Vertigo—Doxorubicin—pancreatic cancer	0.000109	0.000159	CcSEcCtD
Pramipexole—Syncope—Doxorubicin—pancreatic cancer	0.000109	0.000158	CcSEcCtD
Pramipexole—Leukopenia—Doxorubicin—pancreatic cancer	0.000108	0.000158	CcSEcCtD
Pramipexole—Diarrhoea—Docetaxel—pancreatic cancer	0.000108	0.000158	CcSEcCtD
Pramipexole—Confusional state—Epirubicin—pancreatic cancer	0.000108	0.000157	CcSEcCtD
Pramipexole—Palpitations—Doxorubicin—pancreatic cancer	0.000107	0.000156	CcSEcCtD
Pramipexole—Oedema—Epirubicin—pancreatic cancer	0.000107	0.000156	CcSEcCtD
Pramipexole—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000107	0.000155	CcSEcCtD
Pramipexole—Infection—Epirubicin—pancreatic cancer	0.000106	0.000155	CcSEcCtD
Pramipexole—Cough—Doxorubicin—pancreatic cancer	0.000106	0.000154	CcSEcCtD
Pramipexole—Shock—Epirubicin—pancreatic cancer	0.000105	0.000153	CcSEcCtD
Pramipexole—Convulsion—Doxorubicin—pancreatic cancer	0.000105	0.000153	CcSEcCtD
Pramipexole—Nervous system disorder—Epirubicin—pancreatic cancer	0.000105	0.000153	CcSEcCtD
Pramipexole—Dizziness—Docetaxel—pancreatic cancer	0.000105	0.000153	CcSEcCtD
Pramipexole—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000105	0.000152	CcSEcCtD
Pramipexole—Hypertension—Doxorubicin—pancreatic cancer	0.000105	0.000152	CcSEcCtD
Pramipexole—Tachycardia—Epirubicin—pancreatic cancer	0.000104	0.000152	CcSEcCtD
Pramipexole—Skin disorder—Epirubicin—pancreatic cancer	0.000104	0.000151	CcSEcCtD
Pramipexole—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000103	0.00015	CcSEcCtD
Pramipexole—Myalgia—Doxorubicin—pancreatic cancer	0.000103	0.00015	CcSEcCtD
Pramipexole—Chest pain—Doxorubicin—pancreatic cancer	0.000103	0.00015	CcSEcCtD
Pramipexole—Arthralgia—Doxorubicin—pancreatic cancer	0.000103	0.00015	CcSEcCtD
Pramipexole—Anxiety—Doxorubicin—pancreatic cancer	0.000103	0.00015	CcSEcCtD
Pramipexole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000102	0.000149	CcSEcCtD
Pramipexole—Discomfort—Doxorubicin—pancreatic cancer	0.000102	0.000148	CcSEcCtD
Pramipexole—Anorexia—Epirubicin—pancreatic cancer	0.000102	0.000148	CcSEcCtD
Pramipexole—Dry mouth—Doxorubicin—pancreatic cancer	0.000101	0.000147	CcSEcCtD
Pramipexole—Vomiting—Docetaxel—pancreatic cancer	0.000101	0.000147	CcSEcCtD
Pramipexole—Rash—Docetaxel—pancreatic cancer	9.99e-05	0.000145	CcSEcCtD
Pramipexole—Hypotension—Epirubicin—pancreatic cancer	9.99e-05	0.000145	CcSEcCtD
Pramipexole—Dermatitis—Docetaxel—pancreatic cancer	9.99e-05	0.000145	CcSEcCtD
Pramipexole—Confusional state—Doxorubicin—pancreatic cancer	9.97e-05	0.000145	CcSEcCtD
Pramipexole—Headache—Docetaxel—pancreatic cancer	9.93e-05	0.000145	CcSEcCtD
Pramipexole—Oedema—Doxorubicin—pancreatic cancer	9.89e-05	0.000144	CcSEcCtD
Pramipexole—Infection—Doxorubicin—pancreatic cancer	9.83e-05	0.000143	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	9.74e-05	0.000142	CcSEcCtD
Pramipexole—Shock—Doxorubicin—pancreatic cancer	9.73e-05	0.000142	CcSEcCtD
Pramipexole—Nervous system disorder—Doxorubicin—pancreatic cancer	9.7e-05	0.000141	CcSEcCtD
Pramipexole—Thrombocytopenia—Doxorubicin—pancreatic cancer	9.69e-05	0.000141	CcSEcCtD
Pramipexole—Insomnia—Epirubicin—pancreatic cancer	9.67e-05	0.000141	CcSEcCtD
Pramipexole—Tachycardia—Doxorubicin—pancreatic cancer	9.65e-05	0.000141	CcSEcCtD
Pramipexole—Skin disorder—Doxorubicin—pancreatic cancer	9.61e-05	0.00014	CcSEcCtD
Pramipexole—Paraesthesia—Epirubicin—pancreatic cancer	9.6e-05	0.00014	CcSEcCtD
Pramipexole—Hyperhidrosis—Doxorubicin—pancreatic cancer	9.56e-05	0.000139	CcSEcCtD
Pramipexole—Dyspnoea—Epirubicin—pancreatic cancer	9.53e-05	0.000139	CcSEcCtD
Pramipexole—Somnolence—Epirubicin—pancreatic cancer	9.5e-05	0.000138	CcSEcCtD
Pramipexole—Anorexia—Doxorubicin—pancreatic cancer	9.43e-05	0.000137	CcSEcCtD
Pramipexole—Nausea—Docetaxel—pancreatic cancer	9.42e-05	0.000137	CcSEcCtD
Pramipexole—Dyspepsia—Epirubicin—pancreatic cancer	9.41e-05	0.000137	CcSEcCtD
Pramipexole—Decreased appetite—Epirubicin—pancreatic cancer	9.29e-05	0.000135	CcSEcCtD
Pramipexole—Hypotension—Doxorubicin—pancreatic cancer	9.24e-05	0.000135	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Epirubicin—pancreatic cancer	9.23e-05	0.000134	CcSEcCtD
Pramipexole—Fatigue—Epirubicin—pancreatic cancer	9.22e-05	0.000134	CcSEcCtD
Pramipexole—Pain—Epirubicin—pancreatic cancer	9.14e-05	0.000133	CcSEcCtD
Pramipexole—Constipation—Epirubicin—pancreatic cancer	9.14e-05	0.000133	CcSEcCtD
Pramipexole—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	9.01e-05	0.000131	CcSEcCtD
Pramipexole—Insomnia—Doxorubicin—pancreatic cancer	8.95e-05	0.00013	CcSEcCtD
Pramipexole—Paraesthesia—Doxorubicin—pancreatic cancer	8.88e-05	0.000129	CcSEcCtD
Pramipexole—Dyspnoea—Doxorubicin—pancreatic cancer	8.82e-05	0.000128	CcSEcCtD
Pramipexole—Feeling abnormal—Epirubicin—pancreatic cancer	8.81e-05	0.000128	CcSEcCtD
Pramipexole—Somnolence—Doxorubicin—pancreatic cancer	8.79e-05	0.000128	CcSEcCtD
Pramipexole—Gastrointestinal pain—Epirubicin—pancreatic cancer	8.74e-05	0.000127	CcSEcCtD
Pramipexole—Dyspepsia—Doxorubicin—pancreatic cancer	8.71e-05	0.000127	CcSEcCtD
Pramipexole—Decreased appetite—Doxorubicin—pancreatic cancer	8.6e-05	0.000125	CcSEcCtD
Pramipexole—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	8.54e-05	0.000124	CcSEcCtD
Pramipexole—Fatigue—Doxorubicin—pancreatic cancer	8.53e-05	0.000124	CcSEcCtD
Pramipexole—Urticaria—Epirubicin—pancreatic cancer	8.49e-05	0.000124	CcSEcCtD
Pramipexole—Pain—Doxorubicin—pancreatic cancer	8.46e-05	0.000123	CcSEcCtD
Pramipexole—Constipation—Doxorubicin—pancreatic cancer	8.46e-05	0.000123	CcSEcCtD
Pramipexole—Abdominal pain—Epirubicin—pancreatic cancer	8.45e-05	0.000123	CcSEcCtD
Pramipexole—Body temperature increased—Epirubicin—pancreatic cancer	8.45e-05	0.000123	CcSEcCtD
Pramipexole—Feeling abnormal—Doxorubicin—pancreatic cancer	8.15e-05	0.000119	CcSEcCtD
Pramipexole—Gastrointestinal pain—Doxorubicin—pancreatic cancer	8.09e-05	0.000118	CcSEcCtD
Pramipexole—Hypersensitivity—Epirubicin—pancreatic cancer	7.88e-05	0.000115	CcSEcCtD
Pramipexole—Urticaria—Doxorubicin—pancreatic cancer	7.86e-05	0.000114	CcSEcCtD
Pramipexole—Body temperature increased—Doxorubicin—pancreatic cancer	7.82e-05	0.000114	CcSEcCtD
Pramipexole—Abdominal pain—Doxorubicin—pancreatic cancer	7.82e-05	0.000114	CcSEcCtD
Pramipexole—Asthenia—Epirubicin—pancreatic cancer	7.67e-05	0.000112	CcSEcCtD
Pramipexole—Pruritus—Epirubicin—pancreatic cancer	7.56e-05	0.00011	CcSEcCtD
Pramipexole—Diarrhoea—Epirubicin—pancreatic cancer	7.32e-05	0.000106	CcSEcCtD
Pramipexole—Hypersensitivity—Doxorubicin—pancreatic cancer	7.29e-05	0.000106	CcSEcCtD
Pramipexole—Asthenia—Doxorubicin—pancreatic cancer	7.1e-05	0.000103	CcSEcCtD
Pramipexole—Dizziness—Epirubicin—pancreatic cancer	7.07e-05	0.000103	CcSEcCtD
Pramipexole—Pruritus—Doxorubicin—pancreatic cancer	7e-05	0.000102	CcSEcCtD
Pramipexole—Vomiting—Epirubicin—pancreatic cancer	6.8e-05	9.89e-05	CcSEcCtD
Pramipexole—Diarrhoea—Doxorubicin—pancreatic cancer	6.77e-05	9.85e-05	CcSEcCtD
Pramipexole—Rash—Epirubicin—pancreatic cancer	6.74e-05	9.81e-05	CcSEcCtD
Pramipexole—Dermatitis—Epirubicin—pancreatic cancer	6.73e-05	9.8e-05	CcSEcCtD
Pramipexole—Headache—Epirubicin—pancreatic cancer	6.7e-05	9.75e-05	CcSEcCtD
Pramipexole—Dizziness—Doxorubicin—pancreatic cancer	6.54e-05	9.52e-05	CcSEcCtD
Pramipexole—Nausea—Epirubicin—pancreatic cancer	6.35e-05	9.24e-05	CcSEcCtD
Pramipexole—Vomiting—Doxorubicin—pancreatic cancer	6.29e-05	9.16e-05	CcSEcCtD
Pramipexole—Rash—Doxorubicin—pancreatic cancer	6.24e-05	9.08e-05	CcSEcCtD
Pramipexole—Dermatitis—Doxorubicin—pancreatic cancer	6.23e-05	9.07e-05	CcSEcCtD
Pramipexole—Headache—Doxorubicin—pancreatic cancer	6.2e-05	9.02e-05	CcSEcCtD
Pramipexole—Nausea—Doxorubicin—pancreatic cancer	5.88e-05	8.55e-05	CcSEcCtD
Pramipexole—DRD4—Signaling Pathways—VEGFA—pancreatic cancer	1.51e-05	4.83e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CD—pancreatic cancer	1.51e-05	4.83e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—PTEN—pancreatic cancer	1.51e-05	4.82e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PIK3CB—pancreatic cancer	1.5e-05	4.79e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PTEN—pancreatic cancer	1.5e-05	4.79e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—PIK3CA—pancreatic cancer	1.5e-05	4.79e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—STAT3—pancreatic cancer	1.5e-05	4.78e-05	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.5e-05	4.78e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MMP9—pancreatic cancer	1.5e-05	4.78e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—NRAS—pancreatic cancer	1.49e-05	4.77e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CXCL8—pancreatic cancer	1.49e-05	4.77e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PIK3CB—pancreatic cancer	1.49e-05	4.77e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—PTEN—pancreatic cancer	1.49e-05	4.75e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CD—pancreatic cancer	1.49e-05	4.75e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—HRAS—pancreatic cancer	1.48e-05	4.74e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—SRC—pancreatic cancer	1.48e-05	4.74e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—HRAS—pancreatic cancer	1.48e-05	4.73e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—KRAS—pancreatic cancer	1.48e-05	4.73e-05	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.47e-05	4.71e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling by GPCR—AKT1—pancreatic cancer	1.47e-05	4.7e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—KRAS—pancreatic cancer	1.46e-05	4.65e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PIK3CB—pancreatic cancer	1.45e-05	4.64e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling by GPCR—AKT1—pancreatic cancer	1.45e-05	4.64e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—MYC—pancreatic cancer	1.44e-05	4.61e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—VEGFA—pancreatic cancer	1.44e-05	4.61e-05	CbGpPWpGaD
Pramipexole—ADRA2B—GPCR downstream signaling—AKT1—pancreatic cancer	1.44e-05	4.61e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CXCL8—pancreatic cancer	1.44e-05	4.61e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TGFB1—pancreatic cancer	1.44e-05	4.6e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PTEN—pancreatic cancer	1.44e-05	4.59e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CXCL8—pancreatic cancer	1.43e-05	4.58e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—HRAS—pancreatic cancer	1.43e-05	4.58e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—STAT3—pancreatic cancer	1.43e-05	4.57e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CASP3—pancreatic cancer	1.43e-05	4.57e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—NRAS—pancreatic cancer	1.43e-05	4.56e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—HRAS—pancreatic cancer	1.42e-05	4.55e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—MYC—pancreatic cancer	1.41e-05	4.52e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—EGFR—pancreatic cancer	1.41e-05	4.51e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TGFB1—pancreatic cancer	1.41e-05	4.51e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	1.41e-05	4.5e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	1.4e-05	4.48e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—SRC—pancreatic cancer	1.4e-05	4.47e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PTGS2—pancreatic cancer	1.4e-05	4.46e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CXCL8—pancreatic cancer	1.39e-05	4.46e-05	CbGpPWpGaD
Pramipexole—HTR1A—GPCR downstream signaling—AKT1—pancreatic cancer	1.39e-05	4.45e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—MYC—pancreatic cancer	1.39e-05	4.45e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CCND1—pancreatic cancer	1.39e-05	4.44e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TGFB1—pancreatic cancer	1.39e-05	4.44e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—HRAS—pancreatic cancer	1.39e-05	4.43e-05	CbGpPWpGaD
Pramipexole—HTR2C—GPCR downstream signaling—AKT1—pancreatic cancer	1.39e-05	4.43e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—EGFR—pancreatic cancer	1.38e-05	4.42e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CASP3—pancreatic cancer	1.38e-05	4.41e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—SRC—pancreatic cancer	1.38e-05	4.41e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—CTNNB1—pancreatic cancer	1.38e-05	4.4e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CASP3—pancreatic cancer	1.37e-05	4.39e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—VEGFA—pancreatic cancer	1.36e-05	4.35e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—EGFR—pancreatic cancer	1.36e-05	4.35e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—PIK3CA—pancreatic cancer	1.36e-05	4.34e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	1.35e-05	4.32e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MMP9—pancreatic cancer	1.35e-05	4.32e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—STAT3—pancreatic cancer	1.35e-05	4.31e-05	CbGpPWpGaD
Pramipexole—ADRA2C—GPCR downstream signaling—AKT1—pancreatic cancer	1.35e-05	4.31e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—NRAS—pancreatic cancer	1.34e-05	4.3e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—VEGFA—pancreatic cancer	1.34e-05	4.29e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CCND1—pancreatic cancer	1.34e-05	4.29e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PTEN—pancreatic cancer	1.34e-05	4.29e-05	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	1.34e-05	4.28e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.34e-05	4.27e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	1.34e-05	4.27e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CASP3—pancreatic cancer	1.34e-05	4.27e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—KRAS—pancreatic cancer	1.33e-05	4.26e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—STAT3—pancreatic cancer	1.33e-05	4.25e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	1.33e-05	4.25e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—MYC—pancreatic cancer	1.33e-05	4.24e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—NRAS—pancreatic cancer	1.33e-05	4.24e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TGFB1—pancreatic cancer	1.33e-05	4.23e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	1.32e-05	4.23e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	1.32e-05	4.23e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CB—pancreatic cancer	1.32e-05	4.21e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling by GPCR—AKT1—pancreatic cancer	1.31e-05	4.19e-05	CbGpPWpGaD
Pramipexole—DRD5—Signaling Pathways—AKT1—pancreatic cancer	1.31e-05	4.18e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—KRAS—pancreatic cancer	1.31e-05	4.17e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	1.3e-05	4.17e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CCND1—pancreatic cancer	1.3e-05	4.15e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	1.3e-05	4.15e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	1.3e-05	4.14e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	1.3e-05	4.14e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	1.3e-05	4.14e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	1.29e-05	4.12e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—CTNNB1—pancreatic cancer	1.29e-05	4.11e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—KRAS—pancreatic cancer	1.29e-05	4.11e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	1.27e-05	4.04e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	1.26e-05	4.04e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	1.26e-05	4.03e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	1.26e-05	4.02e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	1.26e-05	4.02e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	1.25e-05	4.01e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—MYC—pancreatic cancer	1.25e-05	4e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TGFB1—pancreatic cancer	1.25e-05	3.99e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	1.25e-05	3.98e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	1.25e-05	3.98e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	1.24e-05	3.95e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—MYC—pancreatic cancer	1.24e-05	3.95e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TGFB1—pancreatic cancer	1.23e-05	3.94e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	1.23e-05	3.92e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—PIK3CA—pancreatic cancer	1.23e-05	3.92e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—EGFR—pancreatic cancer	1.23e-05	3.91e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	1.22e-05	3.91e-05	CbGpPWpGaD
Pramipexole—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	1.22e-05	3.91e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PTEN—pancreatic cancer	1.22e-05	3.89e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.22e-05	3.89e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	1.21e-05	3.88e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CASP3—pancreatic cancer	1.21e-05	3.87e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—EGFR—pancreatic cancer	1.21e-05	3.86e-05	CbGpPWpGaD
Pramipexole—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	1.2e-05	3.84e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—SRC—pancreatic cancer	1.2e-05	3.84e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	1.2e-05	3.84e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—PIK3CA—pancreatic cancer	1.2e-05	3.84e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	1.2e-05	3.83e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—SRC—pancreatic cancer	1.2e-05	3.82e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	1.19e-05	3.81e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—TP53—pancreatic cancer	1.19e-05	3.79e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—PIK3CA—pancreatic cancer	1.18e-05	3.77e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CCND1—pancreatic cancer	1.18e-05	3.77e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	1.18e-05	3.77e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	1.17e-05	3.74e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	1.17e-05	3.73e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	1.16e-05	3.72e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	1.16e-05	3.72e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—TP53—pancreatic cancer	1.16e-05	3.71e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	1.16e-05	3.71e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	1.16e-05	3.7e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—KRAS—pancreatic cancer	1.16e-05	3.7e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	1.16e-05	3.69e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	1.15e-05	3.68e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	1.15e-05	3.68e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	1.15e-05	3.67e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MMP9—pancreatic cancer	1.14e-05	3.66e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—TP53—pancreatic cancer	1.14e-05	3.65e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—KRAS—pancreatic cancer	1.14e-05	3.65e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PTEN—pancreatic cancer	1.14e-05	3.64e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	1.13e-05	3.62e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	1.13e-05	3.62e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	1.13e-05	3.62e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	1.13e-05	3.6e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	1.13e-05	3.6e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	1.13e-05	3.6e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	1.12e-05	3.58e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	1.12e-05	3.58e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	1.12e-05	3.58e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	1.12e-05	3.57e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	1.11e-05	3.56e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	1.11e-05	3.55e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	1.11e-05	3.55e-05	CbGpPWpGaD
Pramipexole—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	1.09e-05	3.5e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—HRAS—pancreatic cancer	1.09e-05	3.49e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	1.09e-05	3.49e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	1.09e-05	3.49e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—TP53—pancreatic cancer	1.09e-05	3.49e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—PIK3CA—pancreatic cancer	1.09e-05	3.48e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	1.08e-05	3.46e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—MYC—pancreatic cancer	1.08e-05	3.44e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	1.07e-05	3.43e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—MYC—pancreatic cancer	1.07e-05	3.42e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	1.07e-05	3.42e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	1.06e-05	3.4e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	1.06e-05	3.38e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	1.06e-05	3.37e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—SRC—pancreatic cancer	1.06e-05	3.37e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	1.05e-05	3.37e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—PIK3CA—pancreatic cancer	1.05e-05	3.35e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	1.05e-05	3.35e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	1.05e-05	3.34e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	1.04e-05	3.33e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	1.04e-05	3.33e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	1.04e-05	3.32e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—SRC—pancreatic cancer	1.04e-05	3.32e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	1.03e-05	3.29e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—TP53—pancreatic cancer	1.03e-05	3.29e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	1.03e-05	3.28e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	1.02e-05	3.27e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	1.02e-05	3.26e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	1.02e-05	3.26e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—STAT3—pancreatic cancer	1.02e-05	3.25e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—NRAS—pancreatic cancer	1.02e-05	3.24e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—TP53—pancreatic cancer	1.02e-05	3.24e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—PIK3CA—pancreatic cancer	1.01e-05	3.24e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	1.01e-05	3.23e-05	CbGpPWpGaD
Pramipexole—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	1e-05	3.2e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	1e-05	3.2e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	9.99e-06	3.19e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	9.95e-06	3.18e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	9.94e-06	3.18e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	9.9e-06	3.16e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—HRAS—pancreatic cancer	9.84e-06	3.14e-05	CbGpPWpGaD
Pramipexole—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	9.81e-06	3.13e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—HRAS—pancreatic cancer	9.71e-06	3.1e-05	CbGpPWpGaD
Pramipexole—DRD4—Signaling Pathways—AKT1—pancreatic cancer	9.65e-06	3.08e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	9.63e-06	3.08e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	9.47e-06	3.03e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—MYC—pancreatic cancer	9.46e-06	3.02e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	9.45e-06	3.02e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	9.43e-06	3.01e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—MYC—pancreatic cancer	9.31e-06	2.97e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	9.28e-06	2.97e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—EGFR—pancreatic cancer	9.25e-06	2.96e-05	CbGpPWpGaD
Pramipexole—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	9.21e-06	2.94e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	9.2e-06	2.94e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	9.16e-06	2.93e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	9.14e-06	2.92e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	9.11e-06	2.91e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	9.1e-06	2.91e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	9.1e-06	2.91e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	9.09e-06	2.9e-05	CbGpPWpGaD
Pramipexole—SLC22A2—Metabolism—AKT1—pancreatic cancer	8.89e-06	2.84e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	8.85e-06	2.83e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—TP53—pancreatic cancer	8.85e-06	2.83e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—TP53—pancreatic cancer	8.8e-06	2.81e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	8.76e-06	2.8e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—KRAS—pancreatic cancer	8.74e-06	2.79e-05	CbGpPWpGaD
Pramipexole—DRD1—Signaling Pathways—AKT1—pancreatic cancer	8.69e-06	2.78e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Metabolism—AKT1—pancreatic cancer	8.64e-06	2.76e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	8.6e-06	2.75e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	8.6e-06	2.75e-05	CbGpPWpGaD
Pramipexole—DRD3—Signaling Pathways—AKT1—pancreatic cancer	8.57e-06	2.74e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	8.56e-06	2.73e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	8.47e-06	2.71e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	8.46e-06	2.7e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	8.45e-06	2.7e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	8.42e-06	2.69e-05	CbGpPWpGaD
Pramipexole—SLC22A1—Metabolism—AKT1—pancreatic cancer	8.28e-06	2.65e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	8.28e-06	2.65e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	8.19e-06	2.62e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	8.03e-06	2.57e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	7.9e-06	2.52e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	7.82e-06	2.5e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—TP53—pancreatic cancer	7.77e-06	2.48e-05	CbGpPWpGaD
Pramipexole—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	7.74e-06	2.47e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—TP53—pancreatic cancer	7.64e-06	2.44e-05	CbGpPWpGaD
Pramipexole—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	7.47e-06	2.39e-05	CbGpPWpGaD
Pramipexole—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	7.43e-06	2.37e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—HRAS—pancreatic cancer	7.43e-06	2.37e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	7.31e-06	2.34e-05	CbGpPWpGaD
Pramipexole—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	7.23e-06	2.31e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	7.19e-06	2.3e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Metabolism—AKT1—pancreatic cancer	7.02e-06	2.24e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	6.95e-06	2.22e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	6.65e-06	2.12e-05	CbGpPWpGaD
Pramipexole—DRD2—Signaling Pathways—AKT1—pancreatic cancer	6.56e-06	2.1e-05	CbGpPWpGaD
Pramipexole—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	6.45e-06	2.06e-05	CbGpPWpGaD
Pramipexole—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	5.87e-06	1.88e-05	CbGpPWpGaD
